BioSpace News Archive

POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the completion of enrollment for the randomization phase in the pivotal phase 3 SPLASH trial, on schedule and meeting previous guidance.

Milestone Scientific Inc. today announced it has entered into a distribution agreement with Sweden & Martina , a leading European dental distributor and manufacturer.

RespireRx Pharmaceuticals Inc. is pleased to announce that, on January 11, 2023, it established ResolutionRx Ltd (“ResolutionRx”), a new, currently wholly-owned, unlisted public company in Australia.

Simulations Plus, Inc. today announced that its DILIsym Services (DSS) division has released DILIsym ® version X (DSX) Beta, the latest version of its flagship quantitative systems toxicology (QST) software for predicting and investigating drug-induced liver injury (DILI).

NLS Pharmaceutics Ltd. today announced plans to showcase its global strategic R&D progress and platform, as well as its product candidate and pipeline goals for 2023, with a focus on rare and complex CNS disorders with unmet medical needs.

As part of its efforts to support emerging biotechnology companies with addressing key challenges of bringing new therapies to market, Thermo Fisher Scientific today announced it has become a founding sponsor of Momentum Labs in Alachua, Fla.

AmplifyBio announced that it had augmented its balance sheet with non-dilutive debt financing, whereby it may borrow a principal amount of up to $50 million from Hercules Capital, Inc. (NYSE: HTGC).

Cambrian BioPharma , a multi-asset longevity biotech, today unveils its latest pipeline company, Isterian Biotech.

Neutron Therapeutics (NT) today announced the successful production of a proton beam at an industry-leading 37mA of proton current on target, and the generation of the first neutron beam at its nuBeam® system at Shonan Kamakura General Hospital (SKGH) in Kanagawa Prefecture, Japan.

Looking to harness the potential of non-invasive ultrasound technology, clinicians at Northwell Health and clinical trial investigators at The Feinstein Institutes for Medical Research have begun to participate in the Alpheus™ Medical, Inc phase 1 clinical trial and enrolled its first set of patients at North Shore University Hospital (NSUH).